Cargando…
Milestones for development of tivozanib for kidney cancer therapy
Autores principales: | Crescentini, Robert, Gupta, Shilpa, Fishman, Mayer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708201/ https://www.ncbi.nlm.nih.gov/pubmed/26816699 http://dx.doi.org/10.3978/j.issn.2223-4683.2012.06.08 |
Ejemplares similares
-
Tivozanib: a novel VGFR inhibitor for kidney cancer
por: Boyle, Helen
Publicado: (2013) -
Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?
por: Gross-Goupil, Marine, et al.
Publicado: (2012) -
Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?
por: Mihály, Zsuzsanna, et al.
Publicado: (2012) -
Tivozanib in the treatment of renal cell carcinoma
por: Hepgur, Mehmet, et al.
Publicado: (2013) -
Tivozanib for hepatocellular carcinoma: not likely a new option
por: Estrade, Florian, et al.
Publicado: (2020)